Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
131 hedge funds and large institutions have $423M invested in Intra-Cellular Therapies Inc. in 2016 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 38 reducing their positions, and 31 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 38
11% more call options, than puts
Call options by funds: $16.3M | Put options by funds: $14.8M
6% less funds holding
Funds holding: 139 → 131 (-8)
26% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 31
64% less capital invested
Capital invested by funds: $1.19B → $423M (-$763M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$40.4M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$26.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.4M |
| 4 |
SIM
Spark Investment Management
New York
|
+$8.08M |
| 5 |
Goldman Sachs
New York
|
+$7.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$39.4M |
| 2 |
O
OrbiMed
New York
|
-$35.8M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$25.7M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$20.2M |
| 5 |
BG
BlackRock Group
London,
United Kingdom
|
-$17.4M |
ITCI Hedge Fund Activity: Q3 2016 in Review
131 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2016, worth a combined $423M — down 64% from $1.19B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of ITCI and 23 opened new positions — a net loss of 8 holders — while 38 trimmed existing stakes and 45 added.
The largest buyer was Hillhouse Investment Management, opening a new position worth an estimated $40.4M. The largest seller was BlackRock Advisors, cutting an estimated $39.4M.
- 131 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2016, down from 139 in Q2 2016.
- Funds reported $423M of Intra-Cellular Therapies Inc. stock for Q3 2016, down 64% quarter-over-quarter.
- 23 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2016 and 31 closed out, a net change of -8 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q3 2016 was Hillhouse Investment Management, an estimated $40.4M added.
- The largest Intra-Cellular Therapies Inc. seller in Q3 2016 was BlackRock Advisors, an estimated $39.4M sold.
Based on aggregated 13F filings for Q3 2016.